Adverse reactions and countermeasures during lapatinib treatment

Lapatinib, an oral small molecule drug with dual inhibitory functions, has won widespread attention in the field of breast cancer treatment for its unique mechanism. It can inhibit epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase simultaneously. Since being approved by the US Food and Drug Administration (FDA) in 2007, it has become an important treatment option for patients with advanced or metastatic breast cancer (MBC) with HER2 overexpression.

However, despite the remarkable efficacy of lapatinib, patients may still face the challenge of a series of adverse reactions during treatment. The diversity and inter-individual differences in these reactions require that patients remain highly alert to their condition and engage in ongoing and in-depth communication with their healthcare team when receiving treatment.

Diarrhea and skin problems are commonly reported adverse reactions during lapatinib treatment. The severity of diarrhea may vary from mild to severe depending on the drugs used together. Such adverse events may affect patients' quality of life, reduce treatment compliance, and even lead to treatment interruption. Therefore, aggressive management of diarrhea is crucial, especially in patients who are concurrently receiving other medications that may also trigger diarrhea. Currently, as the application of lapatinib continues to expand, more critical active diarrhea management strategies and dose adjustment methods are gradually being developed to reduce the risk of grade 3 or 4 toxicity.

As for skin-related adverse reactions, although most cases are mild to moderate and of limited duration, and usually do not require special therapeutic intervention, in some patients, proper management of these reactions is still very important.

Overall, although lapatinib may be accompanied by a series of adverse reactions during treatment, through reasonable coping strategies, close doctor-patient communication, and scientific self-management and care, most patients can effectively tolerate and complete the entire treatment process. Patients should fully understand the potential risks of the drug before starting treatment and work closely with the medical team throughout the treatment process to ensure the safety and effectiveness of the treatment.

xa0

Reference: https://openurl.ebsco.com/EPDB%3Agcd%3A6%3A1984390/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A48846598&crl=c&link_origin=scholar.google.co.jp